Frataxin mRNA

Frataxin mRNA is the messenger RNA transcript produced from the FXN gene and encodes frataxin protein. Reduced levels of frataxin mRNA are a hallmark of Friedreich's ataxia, an autosomal recessive neurodegenerative disorder characterized by progressive ataxia and cardiomyopathy. The mRNA itself is not typically a direct therapeutic target; instead, the therapeutic focus is usually on either restoring frataxin protein levels or correcting the genetic defect affecting mRNA production. Frataxin mRNA is predominantly expressed in tissues with high metabolic rates. Decreased synthesis is the result of GAA triplet repeat expansion in intron 1 of the FXN gene, interfering with transcription and resulting in reduced protein levels. While some gene therapy or RNA-targeted strategies may aim to increase frataxin mRNA, the mRNA is not commonly classified among canonical receptors, enzymes, or protein targets[1][6]. Note: - The main therapeutic and biological focus is the **frataxin protein**, not the mRNA itself. - "Frataxin mRNA" is not a canonical target in the standard pharmacological or structural biology sense, but rather refers to the RNA transcript whose reduction leads to disease[1][6]. - If you are seeking structured target information as for receptors or enzymes, the protein "Frataxin" would be a more appropriate canonical target. - There are currently no drugs that directly bind or target frataxin mRNA in approved therapies. Most interventions seek to increase frataxin expression indirectly at the DNA or protein level.

Other names

FXN mRNA